WT1 and neoplasm: Instead, these effectors are restricted to conventional anti-tumor cytotoxicity via targeting tumor-associated antigens, such as MAGE or WT1, or tumor neoantigens, which are scarce in myeloid malignancies given their low relative mutational burden [96,97,98].